Market Highlights
The Americas
Cancer Immunotherapy Market Share is expected to grow at USD 118274.96
Million by 2030 at an approximate CAGR of 13.80% during the forecast period
2022-2030.
Cancer Immunotherapy is an advanced paradigm in cancer
therapeutics. Cancer immunotherapy works by enhancing the patient’s immune
system. This is generally accompanied by the administration of synthesized
immune proteins. The most common therapeutic areas of cancer immunotherapy are
inclusive of breast, prostate, lung cancer, and others. Increasing prevalence
of the cancer is one of the major drivers for the market growth during the
forecast period. Moreover, growing geriatric population and rising healthcare
expenditure, increasing biotech and pharmaceutical sector boosts the market
growth. However, lack of awareness and high cost for the services may restrain
the market growth.
Key Players
Some of the major Americas Cancer Immunotherapy Market
Players in the market are
Amgen Inc. (U.S.),
AstraZeneca (U.K),
F. Hoffmann-La Roche Ltd. (Switzerland),
Bayer AG (Germany),
Bristol-Myers Squibb Company (U.S.),
Eli Lilly and Company (U.S.),
Merck & Co., Inc. (U.S.),
Pfizer Inc. (U.S.),
Novartis AG (Switzerland), and others.
Segmentation
The Americas
cancer immunotherapy market outlook is segmented on the basis of cancer,
therapeutics, and end users.
·
On the basis of the cancer, the market is
segmented into lung cancer, prostate cancer, colorectal cancer, head & neck
cancer, and others.
·
On the basis of the therapeutics, the
market is segmented into monoclonal antibodies, immune checkpoint inhibitors,
vaccines, non-specific cancer immunotherapies and adjuvants, and others.
·
On the basis of the end users, the market
is segmented into hospitals & clinics, academic institutes, research
organization, and others.
Regional Analysis
On regional basis the Americas is divided into North America
and Latin America. North America is sub segmented into U.S. and Canada. North
America commands for the largest market. The large share is also attributed due
to the technologically advanced healthcare market, high prevalence of cancer,
increasing development in cancer immunotherapy treatment and rising per capita
healthcare expenditure. According to the National Cancer Institute in 2016, an
estimated 1,685,210 new cases of cancer were diagnosed in the U.S. and
approximately 595,690 people died due to cancer within the region. This is
projected to drive the healthcare expenditure for cancer. By 2020,
approximately USD 156 billion will invested on the cancer therapeutics and
diagnostics.
On the other hand, Latin America is the fastest growing
region due to the presence of the developing economies within the region,
rising healthcare expenditure along with the huge patient population. Moreover,
the presence of huge opportunities within the region fuels the market growth
during the forecast period.
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
No comments:
Post a Comment